Guangzhou IGE Biotechnology Co., Ltd.
Guangzhou IGE Biotechnology Co., Ltd.
Guangzhou IGE Biotechnology Co., Ltd.
Guangzhou IGE Biotechnology Co., Ltd.
Human leukocyte antigen (HLA) genotyping sequencing
Human leukocyte antigen (HLA), also known as major histocompatibility complex (MHC), is a group of genes that control cell-to-cell recognition and regulate immune responses. HLA is located on the short arm of chromosome 6 (6p21.3), and has a high degree of genetic polymorphism. HLA genes encode cell surface antigen receptors, which are the unique "features" of each person's cells. They are the basis for the immune system to distinguish between self and non-self substances, and are widely used in the research of immune-related diseases, organ and bone marrow transplantation, vaccine and drug target population screening, and tumor immunotherapy.
AiGene Biotechnology has provided a comprehensive HLA genotyping solution based on its self-developed liquid probe hybridization capture technology platform. The platform comprehensively detects 6 HLA genes, including HLA-A, B, C, DRB1, DQB1, and DPB1. It provides more comprehensive and targeted precision genotyping analysis results, to assist scientific research.
Product information
Product name | HLA genotyping |
Target region size | 15.65 kb |
Detection range | HLA-A、B、C、DRB1、DQB1、DPB1 |
Technology platform | TargetSeq? |
Product advantages
◇ High sensitivity：Adopts a highly specific detection method, with high sensitivity and low sample requirements |
◇ High resolution：Achieves 6-digit high-precision genotyping |
◇ Comprehensive detection：Comprehensively covers the full-length sequence of HLA class I molecules (A, B, C) and the full-exonic sequence of HLA class II molecules (DRB1, DQB1, DPB1), with a more comprehensive detection range |
◇ High accuracy：Based on high-throughput sequencing (NGS), avoiding ambiguous results, with more accurate detection results |
◇ Flexible selection：Flexible customization of HLA multi-locus gene detection panel |
技術(shù)路線
技術(shù)參數(shù)
Sample preparation | DNA≥500 ng (concentration≥5 ng/μL), fresh tissue≥20 mg, whole blood (genome DNA extraction)≥1 mL, dried blood spot≥3 pieces (1 cm2 area), saliva≥1 mL, oral swab≥1 piece, fresh cultured cells≥5×106 cells, FFPE (paraffin-embedded sections)≥10 pieces (1 cm2 area, 5-10 μm) |
Capture platform | AI-HLA-Cap |
Sequencing strategy | Illumina PE150 |
Service cycle | 15 natural days |
Literature cases
Loss of heterozygosity of HLA alleles and immune escape phenomenon in the evolution of lung cancer
Journal：Cell IF：31.398 Publication year：2017
Tumor neoantigen recognition is the key to the production of immune response, and the expression and integrity of HLA are the basis for neoantigen presentation. The authors of this article developed a method for analyzing HLA LOH (loss of heterozygosity in human leukocyte antigen), and studied the impact of HLA copy loss of heterozygosity on immune escape from the perspective of lung cancer evolution. Using this method in lung cancer research, it was found that 40% of NSCLCs samples had HLA LOH phenomenon, and it was associated with high clonal neoantigen load, APOBEC-mediated mutations, increased cell lysis activity and PD-L1 positivity. The results further confirmed that HLA LOH is one of the main causes of tumor immune escape.
圖1 非小細胞肺癌（NSCLC）中HLA LOH的表現(xiàn)
參考文獻
Mcgranahan N, Rosenthal R, Hiley C T, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution[J]. Cell, 2017, 171(6):1259-1271.e11.
Copyright ? Guangzhou IGE Biotechnology Co., Ltd.
粵ICP備2021146096號
?
